Publication details
Současný trend chirurgické léčby karcinomu ovaria
| Title in English | Current trend of surgical treatment of ovarian cancer |
|---|---|
| Authors | |
| Year of publication | 2013 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Description | Introduction: Ovarian cancer occurs in all age groups of women. In 2010, the incidence of ovarian cancer, according to NCR (National Cancer Registry) in the Czech Republic 20,4 / 100000 women. Almost 70% of cases are still diagnosed in advanced stages FIGO III - IV. Ovarian cancer represents 47% of deaths from gynecological malignancy. Cancer screening does not exist and all efforts to introduce it proved ineffective. Patients in clinical stage I. achieving 5-year survival in 80-90% of patients in II. clinical stage survive 5 years to 60% in III. clinical stage at 23% in the fourth. clinical stage less than 15%. Objective: The aim is to draw attention to a fundamental change in the surgical treatment of advanced ovarian cancer. Standard staging operations in early ovarian cancer involves lavage of the abdominal cavity with extrafascial hysterectomy with bilateral adnexectomy, underwent total omentektomie, appendectomy and systematic pelvic and paraaortic lymphadenectomy. In advanced ovarian cancer, in addition to staging surgery adds the elimination organs or parts of organs macroscopically affected by cancer. Operating performance is driven by efforts to achieve zero macroscopic postoperative tumor residuals (R0). Discussion: The prognosis of ovarian cancer depends on the extent of disease at detection and differentiation of the tumor. The strongest independent prognostic factor for survival is zero postoperative macroscopic residual tumor. In case of an R0 in FIGO stage IIB - IIIB prolong patient overall survival of 60.3 months in FIGO stage IIIC of 46.9 months and in FIGO stage IV for 30 months. Conclusion: To improve the prognosis of patients with ovarian cancer is the concentration required to oncogynecology centers. It requires a multidisciplinary approach and comprehensive cancer care. Essential for individualization of treatment is to identify patients profit from the primary radical surgical treatment or deferred radical surgery after neoadjuvant chemotherapy 3 series. Zero postoperative residual tumor is the strongest independent prognostic factor for overall survival of patients. |